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Abstract: Depot formulations are not widely used in everyday practice. This
study aimed to assess psychiatrists’ attitudes toward the use of long-acting
injectable (LAI) antipsychotics in schizophrenia. We interviewed 113 French
psychiatrists about the factors that influenced their prescription of LAI anti-
psychotics. Multidimensional and cluster analyses were used to detect corre-
lations. The most important factor against the use of LAI antipsychotics is a
sufficient estimated compliance with the oral formulation. For first-generation
LAI, the main factor is the risk for extrapyramidal symptoms; and for second-
generation LAI, it is the unavailability of the equivalent oral formulation. Four
factors incite the psychiatrists to prescribe LAI. Two different clusters of pa-
tients can also be identified. Most factors influencing the clinicians’ attitudes
toward the use of LAI antipsychotics are shared in many countries. Con-
versely, some attitudes related to organizational aspects, particularly the rele-
vance of health care costs, may vary from one country to another.
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According to systematic reviews, between 40% and 60% of pa-tients with schizophrenia are known to be partially or totally
noncompliant to oral antipsychotic medication (Dolder et al., 2002;
Valenstein et al., 2004). Poor adherence is associated with higher risk
for relapse of schizophrenia and increased health care costs (Patel
et al., 2008).
However, depot formulations are not widely used in routine
practice, with a prescription rate of generally lower than 30% in dif-
ferent countries (Barnes et al., 2009; Patel and David, 2011). However,
the use of long-acting injectable (LAI) formulations varies between
countries. The prescription rates are higher in France (23.5%; Fourrier
et al., 2000) and in the United Kingdom (29%; Barnes et al., 2009)
compared with other European countries and with Canada (6.3%;
Williams et al., 2006) or the United States (17.6%; West et al., 2008).
This discrepancy between countries can be considered to de-
rive from the health care system and from the different attitudes
displayed by psychiatrists.
Perceived coercion or presumed risks for lower tolerance of de-
pot forms have been identified as factors responsible for this low use
(Heres et al., 2006; Patel and David, 2011). More generally, negative
attitudes from practitioners toward these forms have been shown to ac-
count for part of the low prescription rates of depot antipsychotics
(Hamann et al., 2010; Heres et al., 2006, 2008, 2011).
The main goal of our study was to assess the attitudes of psy-
chiatrists toward LAI antipsychotics in patients with schizophrenia
to understand the reasons for using or not assigning depot treatment.
We studied these attitudes in a sample of psychiatrists working in
France using the same questionnaire that was used in a population of
German psychiatrists (Heres et al., 2006, 2008). Our results will be
discussed in the light of the data from the German studies.
METHODS
Procedure and Instruments
At the French Congress of Psychiatry (November 17Y20,
2010, Lyon, France), we questioned French psychiatrists about their
attitudes toward depot antipsychotic treatment. We identified a ran-
domized sample of 150 participants from the global list of partici-
pants (approximately 1500). Six raters were recruited to individually
interview each randomized psychiatrist. All subjects participated
with informed, voluntary, and written consent. When a participant
refused, he/she was replaced by the next on the randomized list. We
stopped inclusions at the end of the congress.
After acceptation, each psychiatrist was interviewed individ-
ually for 40 minutes using a single questionnaire devised by adapting
questionnaires used in two separate studies conducted in different
samples of German psychiatrists (Heres et al., 2006, 2008).
Demographic data were collected (age; sex; number of years
of experience; and type of practice, i.e, hospital or independent).
Each psychiatrist estimated the percentage of patients followed
up in the year 2010 and who were diagnosed with schizophrenia or
schizoaffective disorder. Within this patient group, the percentages of
patients treated with oral first-generation antipsychotics (FGAs) and
second-generation antipsychotics (SGAs) and with LAI FGAs and
SGAs were obtained. The psychiatrists estimated what percentage
of their patients currently taking oral antipsychotics had a low com-
pliance and accepted a prescribed depot formulation.
The psychiatrists in our sample were questioned about the
factors that influenced, negatively or positively, the prescription of
LAI antipsychotics. Misgivings about using depot formulations were
assessed using a 14-item questionnaire. The degree to which each
item influenced the decision to prescribe was scored on a 5-point
Likert scale. We considered a minimum mean rating of 3 in either
the FGA or the SGA category as threshold for the potential impact
of a statement on a psychiatrist’s decision against depot treatment.
A total of 14 items favorably influencing psychiatrists in the
use of depot forms for schizophreniawere presented to the participants.
The degree of influence of each item was evaluated on an 11-point
scale, ranging from 0 (does not influence the prescription of depot
forms) to 10 (very strongly influences the prescription of depot forms).
The choice of an 11-point scale is related to the need to duplicate
the German questionnaire to ensure comparability and the aim to reach
a better level of discrimination between ratings in a domain that is
difficult to assess.
For favorable and unfavorable factors alike, a distinction was
made for each item between LAI formulation of FGAs and SGAs.
Statistical Analysis
Descriptive data were presented using means and standard de-
viation for quantitative variables and proportion for qualitative variables.
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For both questionnaires, means or rating per statement be-
tween FGAs and SGAs were tested using t-tests for paired samples
with two-sided levels of significance of p G 0.003 (postanalyses
Bonferroni’s correction after normality assumption test).
Pearson’s correlation coefficients were calculated for the 14 at-
tributes of the questionnaire designed to evaluate the factors influenc-
ing psychiatrists in the use of LAI formulations for schizophrenia. The
correlation matrix was transformed to measure distance with the metric
multidimensional scaling (MDS). This method transforms a distance
matrix into a set of coordinates. Using the (Euclidean) distances de-
rived from these coordinates, we can approximate the original distances
as accurately as possible. The MDS is used for visualizing correlatio-
nal data; it plots the items on a map so that their correlational structure
is accessible by visual inspection. The ProcMDS in Statistical Analysis
System software was used to determine the graphic representation,
the goodness to fit, and the screeplot. A nonmetric MDS has been
conducted, leading to a two-dimension structure with a better goodness
to fit and the same items distribution among clusters.
RESULTS
Participants
After 3 days of congress, the raters interviewed a total of 139
psychiatrists. One hundred thirteen psychiatrists (53 women and
60 men) accepted and took part in the survey (mean [SD] age, 43.3
[10.5] years; experience, 14.5 [10.9] years), and 26 psychiatrists re-
fused. Most of the participants were hospital practitioners (84.1%),
6.2% have a private practice, and 9.7% combined the two types of
practice. The mean (SD) percentage of patients with a diagnosis of
schizophrenia or schizoaffective disorder followed up in 2010 by the
interviewed practitioners was 33.5% (23.4%). Of these patients, the
mean (SD) percentage of those treated with depot FGAs was 11.3%
(13.8%); with oral FGAs, 18.6% (19.3%); with LAI SGAs, 18.9%
(14.1%); and with oral SGAs, 62.9% (23.4%). The psychiatrists es-
timated that among their patients diagnosed with schizophrenia or
schizoaffective disorder, the mean (SD) proportion of noncompliant
patients was 44.7% (20.6%) and the mean (SD) proportion of all
patients with psychosis treated, of those who would accept a depot
form, was 45.8% (23.9%).
Main Negative Factors Influencing Psychiatrists in
the Prescription of Depot Antipsychotics
The main factors that affect a psychiatrist’s decision against
the use of LAI antipsychotics are shown in Figure 1. We look at the
five factors for which the mean score was 3 points or more. In three of
these, we found a statistically significant difference between FGA and
SGA. The difference was statistically significant in disfavor of FGAs
for high extrapyramidal symptoms (EPSs) risk and first psychotic ep-
isode, whereas the item unavailability of an equivalent of the oral an-
tipsychotic in depot form was statistically more unfavorable to LAI
SGAs than to depot FGAs.
No statistically significant difference was found between the
two types of LAI formulation for the items sufficient compliance
with oral drug and depot recommended but patient refused.
Main Positive Factors Influencing Psychiatrists in the
Prescription of Depot Antipsychotics
The highest scores representing an incentive for psychiatrists
to prescribe LAI (Fig. 2) were the factors hazard risk for others, non-
compliance in the past, relapse in the past, and depot experienced. A
statistically significant difference was found between FGA and SGA
for each of these four items. Hazard risk for others influenced the
psychiatrists more for the prescription of FGAs than of SGAs. By
contrast, the items noncompliance in the past, relapse in the past, and
depot experienced favored the prescription of SGAs more than of
FIGURE 1. Extent of the influence of 14 statements on depot antipsychotic on decision against prescription of long-acting
formulation in the treatment of schizophrenia.
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FGAs. The items suicidal risk, high level of education, first psycho-
tic episode, and unclear diagnosis exerted a low degree of influence on
the decision of the psychiatrist to prescribe a depot form. There was
a significant difference between the two classes, in favor of SGAs, for
the items suicidal risk, and first psychotic episode.
An MDS analysis was carried out, distinguishing the data for
FGAs from the data for SGAs. For depot forms of FGAs, the MDS
points to a distribution of factors into two different clusters that are
related to a positive influence on psychiatrists for the prescription
of LAI (Fig. 3). The two-cluster configuration, taking into account
only the results obtained for the LAI SGAs, also showed these two
clusters, except for the item hazard risk for others, which, in this case,
was found not to belong to cluster I.
DISCUSSION
Reasons for Nonuse of Depot Medication
The main reasons for not choosing an LAI antipsychotic,
whichever the type (FGA or SGA), were that the patient refused and
sufficient compliance with oral drug. These two factors are associ-
ated with mistaken beliefs held by psychiatrists.
Literature data are conflicting with regard to patient accep-
tance of depot forms. Several studies in the 1990s (Hoencamp et al.,
1995; Pereira and Pinto, 1997; Wistedt, 1995) found a preference
among patients for depot forms over oral forms at a time when the
SGAs were still in low use and when there was no available LAI
formulation of SGAs. In review (Walburn et al., 2001), the authors
concluded that quality of data was poor, and surveys from represen-
tative samples of patients on maintenance antipsychotic medication
were needed.
The psychiatrists questioned in our survey considered that
46% of patients would accept a depot form. In reality, a survey of
patients with schizophrenia found that the acceptance rate of LAI
in relapse prevention depended on their experience with this kind
of formulation (Heres et al., 2007). Acceptance rates were 73% in pa-
tients currently being treated with depot, 45% in depot-experienced
patients, and 23% in depot-naive patients.
The level of information from psychiatrists may thus contri-
bute to the attitudes of patients toward depot forms and their accep-
tance rate. The psychiatrists estimate the acceptance rate to be 46%,
which is possible, but they may offer it exactly to the wrong patients.
The psychiatrists also underestimated poor compliance rates
(45% of patients) similar to those in the German study (44% of pa-
tients; Heres et al., 2008). This finding has been reported in several
studies (Heres et al., 2008; Llorca, 2008; Remington et al., 2007).
This belief is associated with the reluctance of psychiatrists to use
depot antipsychotics when patients show good compliance with the
oral drug form. Even worseVif psychiatrists really think that patients
are poorly compliant, they still underuse depot in these patients (West
et al., 2008).
Other deterrents to use depot medication seem to be related to
the class of antipsychotic drug. Although depot FGAs are avoided
because of a high risk for EPSs, LAI SGAs are less widely used be-
cause of a low availability of drugs such as aripiprazole, quetiapine,
amisulpride, and clozapine. These two attitudes are associated be-
cause, in accordance with guidelines (Barnes, 2011; Falkai et al., 2006;
FIGURE 3. MDS analysis of correlation of ratings for LAI FGAs.
FIGURE 2. Mean rating of the attributes potentially influencing the qualification for depot treatment.
The Journal of Nervous and Mental Disease & Volume 201, Number 7, July 2013 Clinicians’ Attitudes Toward Depot
* 2013 Lippincott Williams & Wilkins www.jonmd.com 555
Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Kreyenbuhl et al., 2010), psychiatrists consider the safety-efficacy
ratio of SGA as more favorable than FGA for first-line use. Recent
or future registrations (by country) of olanzapine LAI and paliperidone
palmitate and the development of depot aripiprazole could overcome
this reluctance.
The practitioners questioned in this work emphasize first
psychotic episode as a limiting factor in the use of depot forms. This
result confirms those obtained from German psychiatrists (Fig. 5;
Heres et al., 2006, 2011). Scientific data underlined that the use of
LAI SGAs as early as the first psychotic episode offers many ad-
vantages in terms of efficacy and tolerance (Emsley et al., 2008a,
2008b; Kim et al., 2008). Improving adherence seems to be partic-
ularly important early on in the disease, with greater improvement in
clinical outcomes in patients treated with risperidone LAI (RLAI)
who were recently diagnosed with schizophrenia than in those with
chronic schizophrenia (Olivares et al., 2009). Otherwise, recent studies
demonstrated the superiority of RLAI, compared with the oral form,
to maintain frontal lobe myelinization, to increase frontal lobe intracor-
tical myelin, and to improve cognitive performance in the first psy-
chotic episode (Bartzokis et al., 2011, 2012).
However, the available literature presents a weak level of evi-
dence (open label, post hoc analysis, and small sample), and studies
with high methodology quality are needed to confirm these results.
This lack of evidence can explain the clinicians’ negative attitudes
toward LAI formulation.
A comparison of our results with those of the German sur-
veys shows two main differences concerning reluctance to use depot
forms (Fig. 4).
Firstly, the cost of drugs is not taken into account in the de-
cision to prescribe a depot antipsychotic by French psychiatrists
(although allowance for cost is significantly higher for LAI SGAs).
In contrast, for German psychiatrists, the cost of LAI SGAs is a
strong argument against their use. This difference can be explained
by the specificity of the health care system in each country (i.e., the
French health care system recognizes schizophrenia as a ‘‘long-term
disorder’’ qualifying for full health insurance cover with 100% re-
imbursement of drug costs).
Secondly, poorer control of effect with the depot form com-
pared with the oral drug is considered by German psychiatrists, unlike
the French, as a strong argument against using depot antipsychotics.
This difference in attitude is probably linked to the level of
knowledge and habits of use of depot forms. Patel et al. (2009) em-
phasize the correlation between knowledge and attitudes in using
depot antipsychotics. The training programs for young psychia-
trists in the last 15 years (Heres et al., 2006) and habits of prescrip-
tion of this form by older psychiatrists are probably different in France
and in Germany.
Factors Favoring the Prescription of Depot Forms
The MDS carried out on our results confirms the results ob-
tained in a previous study (Heres et al., 2008), showing two clusters of
factors preferentially taken into account by psychiatrists for the pre-
scription of a depot form. Cluster I corresponds to patients with a history
of relapse and poor compliance with oral forms. These patients present
a less favorable medical prognosis, and this cluster corresponds to the
classic profile of patients in whom depot forms are used. However, the
occurrence of cluster II, corresponding to patients whose profile features
a high level of insight and a high level of therapeutic alliance, is more
unexpected. This cluster seems to be strongly opposed to cluster I, yet
it is taken into account by the psychiatrists in the survey as decisive in
FIGURE 4. Mean rating of the attributes potentially influencing negatively the qualification for depot treatment. Comparison
between French and German data (Heres et al., 2006).
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prescribing a depot form. This cluster also doubtlessly corresponds to
patients whose compliance with oral forms is probably the best (Llorca,
2008). We can readily suppose therefore that the impact of this cluster
in the decision of the psychiatrist to use a depot form owes as much to the
ease with which such patients can be informed about and convinced of
the pharmacological utility of depot forms (in particular, more stable
plasma levels) as to any expected gain in compliance (McEvoy, 2006).
The usefulness of depot forms compared with oral treatment in terms of
relapse prevention is not documented in this population category relative
to the previous one (Heres et al., 2008). However, we note that even
limited poor compliance with oral forms is enough to increase the risk
for relapse considerably (risk for relapse multiplied by 2.81 for a non-
compliance of only 11 to 30 days; Weiden et al., 2004).
It is also interesting to note that these two clusters appear for
LAI formulation of both first and second generation. However, a dif-
ference was found for the SGAs, for which the factor hazard risk for
others was not statistically correlated with the other factors in cluster
I as it was for the FGAs. This finding suggests a preferential use of
LAI formulations of SGAs for long-term treatment of schizophrenia,
and use of FGAs may be more often prescribed for patients with be-
havioral disorders to curb impulsiveness and aggressiveness.
Risk for suicide did not appear to be a factor favorably in-
fluencing the participants in our study for the prescription of depot
forms, in contrast to the results obtained in Germany (Fig. 5; Heres
et al., 2008). It is hard to offer any convincing explanation for this
difference. Even so, we can advance the hypothesis that a) a patient’s
impulse to act may carry greater weight for German psychiatrists and
lead to a more ready recourse to depot forms and b) there is a more
frequent evaluation of depressive comorbidity by French psychiatrists,
leading to greater use of antidepressant treatments. To our knowledge,
no drug epidemiological data are available by which this hypothe-
sis could be tested. It implies different prescription habits linked to
differences in psychiatric training provisions in the two countries. More
generally, data on the utility of antipsychotics in reducing risk for sui-
cide in patients with schizophrenia are, although appreciably favorable,
still limited, except for clozapine, the only antipsychotic treatment
approved by the Food and Drug Administration for this indication
(Kasckow et al., 2011; Meltzer et al., 2003).
Cultural Aspects
The organization of health care could be an important factor
in shaping the attitude of psychiatrists toward depot forms and will
differ between countries.
In France, psychiatric health care provision can be considered
as quantitatively abundant, particularly in terms of equipment and hu-
man resources. Public hospital care makes up 80% of the psychiatric
activity of health care providers, with a network organization based on
the ‘‘psychiatric sector.’’ It dispenses and coordinates all preventive and
postcure care and rehabilitation over the surrounding geodemographic
area. The 815 psychiatric sectors in France allow, in particular, the use
of depot antipsychotics from outpatient services (medicopsychological
centers) or part-time structures (day hospitals and part-time reception
centers). This organization of health care facilitates the practical ap-
plication of a depot antipsychotic prescription.
FIGURE 5. Mean rating of the attributes potentially influencing positively the qualification for depot treatment. Comparison
between French and German data (Heres et al., 2008).
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In Germany, patients with a psychiatric disorder can be treated
either in specialized psychiatric hospitals or in psychiatric units within
general hospitals. The total capacity of beds went down from 117.596
in the year 1972 (West Germany only) to 54.088 in the year 2005
(reunited Germany), also varying markedly between German districts
(1.4/1000 inhabitants in Berlin to 0.4/1000 inhabitants in Sachsen-
Anhalt). Outpatient treatment is offered by psychiatrists or neurolo-
gists in private practices; outpatient clinics; and specialized outpatient
departments, so-called Psychiatrische Institutsambulanzen, which do
offer additional treatment options apart from the sole physicians’ care,
for example, social workers, psychologists, or mental nursing staff. The
specialized outpatient departments are not restricted in the use of anti-
psychotic drugs by a set budget, whereas the other outpatient facilities
are limited in the amount of money they are allowed to spend for
medication expenses. This leads to the situation that costly depot anti-
psychotics, mainly SGA in long-acting formulation, are underlying
limitations in their use through these budget restrictions, in addition
to other factors limiting their use.
Training of psychiatrists can also differ between countries and
may affect their attitudes toward medication in clinical practice.
Nevertheless, if each country has its own health care system
or training program, our results demonstrate that clinicians’ attitudes
toward LAI are rather similar.
Limitations
The participants of our survey may be not necessarily represen-
tative of all psychiatrists. All participants were French psychiatrists,
which limits our ability to generalize results within others countries.
No attempt was made to verify data on prescription rates or
diagnosis frequency reported by the psychiatrists because the field
of this study was on the subjective attitude toward depot treatment.
CONCLUSIONS
We see that the attitudes of psychiatrists toward depot forms
are somewhat negative, and their knowledge of them is patchy. How-
ever, the studies reported in the literature that compare relapse rates
under oral and depot antipsychotics are highly favorable to depot
forms. In an evidence-based clinical approach, psychiatrists should
thus be systematically offering all patients with schizophrenia, in a
shared decision making, a depot antipsychotic as first-line treatment.
This is not what happens in practice, however, and the rate of pre-
scription of these drugs is still low, although there are differences be-
tween countries. It seems that many factors are common in various
countries (misgivings and positive attitudes). Conversely, attitudes con-
nected with organizational aspects, particularly the relevance of health
care costs, may vary from one country to another.
ACKNOWLEDGMENTS
The authors thank E. Berenguer, F. Cyprien, H. Ho Quoc, O.
Lorabi, H. Sananes, and all participants for the time they spent on
this survey.
DISCLOSURES
Dr Heres has received honoraria from Janssen-Cilag, Sanofi-
aventis, Pharmastar, and Johnson & Johnson. Dr Llorca has received
honoraria and/or research support from Janssen-Cilag, AstraZeneca,
Bristol-Myers Squibb, and Eli Lilly. Dr Samalin has received honoraria
from Janssen-Cilag and AstraZeneca. Dr Charpeaud and O. Blanc
declare no conflict of interest.
REFERENCES
Barnes TR (2011) Evidence-based guidelines for the pharmacological treatment
of schizophrenia: Recommendations from the British Association for Psycho-
pharmacology. J Psychopharmacol. 25:567Y620.
Barnes TR, Shingleton-Smith A, Paton C (2009) Antipsychotic long-acting injec-
tions: Prescribing practice in the UK. Br J Psychiatry Suppl. 52:S37YS42.
Bartzokis G, Lu PH, Amar CP, Raven EP, Detore NR, Altshuler LL,Mintz J, Ventura J,
Casaus LR, Luo JS, Subotnik KL, Nuechterlein KH (2011) Long acting injec-
tion versus oral risperidone in first-episode schizophrenia: Differential impact
on white matter myelination trajectory. Schizophr Res. 132:35Y41.
Bartzokis G, Lu PH, Raven EP, Amar CP, Detore NR, Couvrette AJ, Mintz J, Ventura J,
Casaus LR, Luo JS, Subotnik KL, Nuechterlein KH (2012) Impact on intracortical
myelination trajectory of long acting injection versus oral risperidone in first-episode
schizophrenia. Schizophr Res. 140:122Y128.
Dolder CR, Lacro JP, Dunn LB, Jeste DV (2002) Antipsychotic medication adherence:
Is there a difference between typical and atypical agents? Am J Psychiatry.
159:103Y108.
Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J (2008a)
Oral versus injectable antipsychotic treatment in early psychosis: Post hoc
comparison of two studies. Clin Ther. 30:2378Y2386.
Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J (2008b)
Remission in patients with first-episode schizophrenia receiving assured anti-
psychotic medication: A study with risperidone long-acting injection. Int Clin
Psychopharmacol. 23:325Y331.
Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ (2006)
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines
for biological treatment of schizophrenia, part 2: Long-term treatment of
schizophrenia. World J Biol Psychiatry. 7:5Y40.
Fourrier A, Gasquet I, Allicar MP, Bouhassira M, Lepine JP, Begaud B (2000) Pat-
terns of neuroleptic drug prescription: A national cross-sectional survey of
a random sample of French psychiatrists. Br J Clin Pharmacol. 49:80Y86.
Hamann J, Mendel R, Heres S, Leucht S, Kissling W (2010) How much more
effective do depot antipsychotics have to be compared to oral antipsychotics
before they are prescribed? Eur Neuropsychopharmacol. 20:276Y279.
Heres S, Hamann J, Kissling W, Leucht S (2006) Attitudes of psychiatrists toward
antipsychotic depot medication. J Clin Psychiatry. 67:1948Y1953.
Heres S, Hamann J, Mendel R, Wickelmaier F, Pajonk FG, Leucht S, Kissling W
(2008) Identifying the profile of optimal candidates for antipsychotic depot
therapy A cluster analysis. Prog Neuropsychopharmacol Biol Psychiatry.
32:1987Y1993.
Heres S, Reichhart T, Hamann J, Mendel R, Leucht S, Kissling W (2011) Psychi-
atrists’ attitude to antipsychotic depot treatment in patients with first-episode
schizophrenia. Eur Psychiatry. 26:297Y301.
Heres S, Schmitz FS, Leucht S, Pajonk FG (2007) The attitude of patients towards
antipsychotic depot treatment. Int Clin Psychopharmacol. 22:275Y282.
Hoencamp E, Knegtering H, Kooy J, Van der Molen A (1995) Patient requests and
attitude towards neuroleptics. Nord J Psychiatry. 49:47Y55.
Kasckow J, Felmet K, Zisook S (2011) Managing suicide risk in patients with
schizophrenia. CNS Drugs. 25:129Y143.
Kim B, Lee SH, Choi TK, Suh S, Kim YW, Lee E, Yook KH (2008) Effectiveness
of risperidone long-acting injection in first-episode schizophrenia: In natural-
istic setting. Prog Neuropsychopharmacol Biol Psychiatry. 32:1231Y1235.
Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB (2010) The Schizophrenia
Patient Outcomes Research Team (PORT): Updated treatment recommenda-
tions 2009. Schizophr Bull. 36:94Y103.
Llorca PM (2008) Partial compliance in schizophrenia and the impact on patient
outcomes. Psychiatry Res. 161:235Y247.
McEvoy JP (2006) Risks versus benefits of different types of long-acting inject-
able antipsychotics. J Clin Psychiatry. 67(suppl 5):15Y18.
Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois
M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S
(2003) Clozapine treatment for suicidality in schizophrenia: International Sui-
cide Prevention Trial (InterSePT). Arch Gen Psychiatry. 60:82Y91.
Olivares JM, Peuskens J, Pecenak J, Resseler S, Jacobs A, Akhras KS (2009) Clin-
ical and resource-use outcomes of risperidone long-acting injection in recent
and long-term diagnosed schizophrenia patients: Results from a multinational
electronic registry. Curr Med Res Opin. 25:2197Y2206.
Patel MX, David A (2011) Why aren’t depot antipsychotics prescribed more often
and what can be done about it? Adv Psychiatr Treat. 11:203Y213.
Patel MX, de Zoysa N, Bernadt M, David AS (2008) A cross-sectional study of
patients’ perspectives on adherence to antipsychotic medication: Depot versus
oral. J Clin Psychiatry. 69:1548Y1556.
Patel MX, Taylor M, David AS (2009) Antipsychotic long-acting injections: Mind
the gap. Br J Psychiatry Suppl. 52:S1YS4.
Samalin et al. The Journal of Nervous and Mental Disease & Volume 201, Number 7, July 2013
558 www.jonmd.com * 2013 Lippincott Williams & Wilkins
Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Pereira S, Pinto R (1997) A survey of the attitudes of chronic psychiatric patients
living in the community toward their medication. Acta Psychiatr Scand.
95:464Y468.
Remington G, Kwon J, Collins A, Laporte D, Mann S, Christensen B (2007) The
use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in
outpatients with schizophrenia. Schizophr Res. 90:229Y237.
Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L, Bingham
CR, Stavenger T (2004) Poor antipsychotic adherence among patients with
schizophrenia: Medication and patient factors. Schizophr Bull. 30:255Y264.
Walburn J, Gray R, Gournay K, Quraishi S, David AS (2001) Systematic review
of patient and nurse attitudes to depot antipsychotic medication. Br J Psychi-
atry. 179:300Y307.
Weiden PJ, Kozma C, Grogg A, Locklear J (2004) Partial compliance and risk of
rehospitalization among California Medicaid patients with schizophrenia.
Psychiatr Serv. 55:886Y891.
West JC, Marcus SC, Wilk J, Countis LM, Regier DA, Olfson M (2008) Use of
depot antipsychotic medications for medication nonadherence in schizophre-
nia. Schizophr Bull. 34:995Y1001.
Williams R, Kopala L, Malla A, Smith G, Love L, Balshaw R (2006) Medication
decisions and clinical outcomes in the Canadian National Outcomes Mea-
surement Study in Schizophrenia. Acta Psychiatr Scand Suppl. 430:
12Y21.
Wistedt B (1995) How does the psychiatric patient feel about depot treatment,
compulsion or help? Nordic J Psychiatry. 49:41Y46.
The Journal of Nervous and Mental Disease & Volume 201, Number 7, July 2013 Clinicians’ Attitudes Toward Depot
* 2013 Lippincott Williams & Wilkins www.jonmd.com 559
Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
